Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2007

View Archived Issues

Takeda reports first half ended September 30, 2007 results

DOR BioPharma enters cooperative agreement for RiVax with Walter Reed Army Institute

PhotoCure to de-merge its cancer-focused drug delivery subsidiary PCI Biotech

Phase III clinical study of ALK-Abello's grass pollen vaccine fails to meet primary endpoint

Peregrine receives approval in Georgia to initiate phase II trial of bavituximab

European Commission endorses positive opinion of EMEA for sanofi-aventis' Acomplia

EMEA grants orphan drug status to Vx-001 for non-small cell lung cancer

Celgene acquires Pharmion

Quark initiates phase I clinical trial of AKIi-5 for acute renal failure

BioXell initiates phase IIa trial of elocalcitol for male infertility

Takeda establishes Takeda San Francisco for therapeutic antibody research

KCNQ2/3 channel opener from ICAgen shows activity in pain in vivo models

NIAID sponsors phase I trial of Avant's E. coli-cholera vaccine Peru-15 pCTB

Small peptide inhibitor of PKC gamma shows activity in neuropathic pain models

Inflazyme sells majority of its research and development assets to Biolipox

Novel therapeutic agents for respiratory and allergic disorders described in recent patents

Recent Novartis patent discloses novel agents for renal failure

Studies describe novel non-nucleoside HCV RNA polymerase inhibitor GS-9190

Benefits of ranolazine treatment seen in MERLIN-TIMI 36 trial

AZD-9056 studied in healthy volunteers and rheumatoid arthritis patients

AMG-108 not significantly effective in knee osteoarthritis patients

Targeted Genetics releases findings from study of tgAAC94 in inflammatory arthritis

Actelion patents novel dual orexin OX1/OX2 receptor antagonists for eating disorders

Marketing and sale of Novartis' Prexige suspended in U.K. and Germany

FDA approves supplemental NDA for Avalide for hypertension

Chugai and Roche file FDA BLA for Actemra in RA indication

CHMP recommends Merck, Sharp and Dohme's Ivemend for nausea with chemotherapy

Abilify receives FDA approval for adjunctive treatment of MDD

MSD's Isentress for HIV-1 infection gets positive opinion from CHMP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...